A model for evaluating topical antimicrobial efficacy against methicillin-resistant Staphylococcus aureus biofilms in superficial murine wounds.
A wound biofilm model was created by adapting a superficial infection model. Partial-thickness murine wounds were inoculated with methicillin-resistant Staphylococcus aureus (MRSA). Dense biofilm communities developed at the wound surface after 24 h as demonstrated by microscopy and quantitative microbiology. Common topical antimicrobial agents had reduced efficacy when treatment was initiated 24 h after inoculation compared to 4 h after inoculation. This model provides a rapid in vivo test for new agents to treat wound biofilm infections.
Research and Development, Healthpoint Biotherapeutics, Fort Worth, Texas, USA. eric.roche@healthpoint.com
Eric D
ED
Roche
Paul J
PJ
Renick
Shannon P
SP
Tetens
Dennis L
DL
Carson
D000287:Administration, Topical; D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage* / Q000494:pharmacology; D001414:Bacitracin / Q000008:administration & dosage / Q000494:pharmacology; D018441:Biofilms / Q000187:drug effects*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000502:physiology; D051379:Mice; D016712:Mupirocin / Q000008:administration & dosage / Q000494:pharmacology; D018030:Silver Compounds / Q000008:administration & dosage / Q000494:pharmacology; D012837:Silver Sulfadiazine / Q000008:administration & dosage / Q000494:pharmacology; D014946:Wound Infection / Q000188:drug therapy / Q000382:microbiology*
D000891:Anti-Infective Agents, Local; D018030:Silver Compounds; D001414:Bacitracin; D016712:Mupirocin; D012837:Silver Sulfadiazine